Liven Pharmaceuticals Limited (PSX:LIVEN)

Liven Pharmaceuticals Income Statement

Financials in millions PKR. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cost of Revenue	82.76	-	-	-	-	0.32
Gross Profit	38.03	-	-	-	-	-0.32
Selling, General & Admin	26.61	2	2.12	2.95	2.1	1.85
Other Operating Expenses	-	-	-	-	-	17.84
Operating Expenses	38.4	13.79	15.22	17.51	18.19	19.69
Operating Income	-0.36	-13.79	-15.22	-17.51	-18.19	-20.01
Interest Expense	-0.01	-	-	-	-	-
Other Non Operating Income (Expenses)	119.3	-	-0	-0	-0	-0
EBT Excluding Unusual Items	118.92	-13.79	-15.23	-17.51	-18.19	-20.02
Pretax Income	118.92	-13.79	-15.23	-17.51	-18.19	-20.02
Income Tax Expense	11.12	-2.61	-2.9	-3.22	-3.55	-3.09
Net Income	107.8	-11.18	-12.33	-14.29	-14.63	-16.93
Net Income to Common	107.8	-11.18	-12.33	-14.29	-14.63	-16.93
Shares Outstanding (Basic)	57	12	12	12	12	12
Shares Outstanding (Diluted)	57	12	12	12	12	12
EPS (Basic)	1.90	-0.92	-1.02	-1.18	-1.21	-1.40
EPS (Diluted)	1.90	-0.92	-1.02	-1.18	-1.21	-1.40
EBITDA	22.44	-2	-2.12	-2.95	-2.1	-2.14
D&A For EBITDA	22.8	11.79	13.1	14.56	16.08	17.87
EBIT	-0.36	-13.79	-15.22	-17.51	-18.19	-20.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.